C Arnold Spek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3424652/publications.pdf

Version: 2024-02-01

196 papers	5,834 citations	66343 42 h-index	98798 67 g-index
200 all docs	200 docs citations	200 times ranked	7126 citing authors

#	Article	IF	Citations
1	Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 769-782.	5.6	9
2	Macrophage C/EBPÎ´ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner. Biomedicines, 2022, 10, 219.	3.2	4
3	Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Pharmaceutics, 2022, 14, 390.	4.5	11
4	Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation. Respiratory Research, 2022, 23, .	3.6	6
5	Alveolar epithelial TET2 is not involved in the development of bleomycinâ€induced pulmonary fibrosis. FASEB Journal, 2021, 35, e21599.	0.5	1
6	Proteaseâ€activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma. Molecular Oncology, 2021, 15, 3091-3108.	4.6	2
7	ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers, 2021, 13, 3321.	3.7	11
8	Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation. Biomolecules, 2021, 11, 1079.	4.0	4
9	CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs. Cells, 2021, 10, 2233.	4.1	15
10	Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-Î± secretion. BMC Cancer, 2020, 20, 1183.	2.6	21
11	CCAAT/Enhancer-Binding Protein Delta (C/EBPÎ´): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells. Cancers, 2020, 12, 2546.	3.7	11
12	Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cellular Oncology (Dordrecht), 2020, 43, 1161-1174.	4.4	40
13	Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients. Signal Transduction and Targeted Therapy, 2020, 5, 253.	17.1	0
14	Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?. European Respiratory Journal, 2020, 55, 2000811.	6.7	0
15	Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?. Biology, 2020, 9, 80.	2.8	45
16	Pharmacological PARâ€1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy. FASEB Journal, 2019, 33, 10966-10972.	0.5	7
17	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. Journal of Clinical Medicine, 2019, 8, 1547.	2.4	30
18	Smoothened-dependent and -independent pathways in mammalian noncanonical Hedgehog signaling. Journal of Biological Chemistry, 2019, 294, 9787-9798.	3.4	17

#	Article	IF	Citations
19	Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate. ERJ Open Research, 2019, 5, 00157-2018.	2.6	7
20	Proteaseâ€activated receptorâ€1 impedes prostate and intestinal tumor progression in mice: comment. Journal of Thrombosis and Haemostasis, 2019, 17, 235-238.	3.8	3
21	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis, 2019, 40, 155-163.	2.8	9
22	Proteaseâ€activated receptorâ€1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy. Journal of Cellular and Molecular Medicine, 2019, 23, 1268-1279.	3.6	33
23	Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia. Journal of Infectious Diseases, 2018, 217, 1462-1471.	4.0	11
24	Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice. Oncotarget, 2018, 9, 21655-21662.	1.8	10
25	PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget, 2018, 9, 32010-32023.	1.8	25
26	Abstract 5225: PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. , 2018, , .		0
27	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 2018, 3, 358-365.	0.3	3
28	Targeting coagulation factor receptors â€“ proteaseâ€activated receptors in idiopathic pulmonary fibrosis. Journal of Thrombosis and Haemostasis, 2017, 15, 597-607.	3.8	42
29	Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer. BMC Cancer, 2017, 17, 113.	2.6	10
30	Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thrombosis Research, 2017, 154, 1-6.	1.7	10
31	CCAAT/Enhancer Binding Protein Delta exerts tumor-supportive effects but is down-regulated in patient hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S640.	3.7	0
32	Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner. Biochemistry and Biophysics Reports, 2017, 10, 152-156.	1.3	7
33	Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice. Molecular Medicine, 2017, 23, 13-23.	4.4	17
34	Detrimental role for matrix metalloprotease-1 in the pathogenesis of pulmonary fibrosis. , 2017, , .		0
35	Protease activated receptor 2 in diabetic nephropathy: a double edged sword. American Journal of Translational Research (discontinued), 2017, 9, 4512-4520.	0.0	4
36	PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research, 2016, 140, S186-S187.	1.7	2

#	Article	IF	Citations
37	Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice. Scientific Reports, 2016, 6, 33030.	3.3	34
38	High endogenous activated protein C levels attenuates bleomycinâ€induced pulmonary fibrosis. Journal of Cellular and Molecular Medicine, 2016, 20, 2029-2035.	3.6	13
39	Detrimental role for CCAAT/enhancer binding protein Î´ in blood-borne brain infection. BMC Infectious Diseases, 2016, 16, 670.	2.9	1
40	PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. Scientific Reports, 2015, 5, 14534.	3.3	40
41	Authors' replyâ€"Re: Shi et al. Proteaseâ€activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398â€"409. Journal of Pathology, 2015, 236, 130-130.	4.5	0
42	Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. Thrombosis and Haemostasis, 2015, 114, 530-536.	3.4	17
43	Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis. Molecular Medicine, 2015, 21, 576-583.	4.4	24
44	CCAAT/enhancer-binding protein Î´ (C/EBPÎ´) aggravates inflammation and bacterial dissemination during pneumococcal meningitis. Journal of Neuroinflammation, 2015, 12, 88.	7.2	6
45	Lipid droplets hypertrophy: a crucial determining factor in insulin regulation by adipocytes. Scientific Reports, 2015, 5, 8816.	3.3	23
46	Proteaseâ€activated receptor (<scp>PAR</scp>)â€2 is required for <scp>PAR</scp>â€1 signalling in pulmonary fibrosis. Journal of Cellular and Molecular Medicine, 2015, 19, 1346-1356.	3.6	21
47	Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1257-1259.	5.6	5
48	Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget, 2015, 6, 35304-35314.	1.8	20
49	Protease Activated Receptor-1 Deficiency Diminishes Bleomycin-Induced Skin Fibrosis. Molecular Medicine, 2014, 20, 410-416.	4.4	18
50	The Effect of Levothyroxine on Expression of Inflammation-Related Genes in Healthy Subjects: A Controlled Randomized Crossover Study. Hormone and Metabolic Research, 2014, 46, 789-793.	1.5	6
51	CCAAT-enhancer binding protein delta (C/EBPÎ´) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Laboratory Investigation, 2014, 94, 89-97.	3.7	15
52	A polymorphism in the gene for protein tyrosine phosphatase 1b is associated with altered lipid profile and myocardial infarction. Atherosclerosis, 2014, 235, e131.	0.8	0
53	Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. Journal of Pathology, 2014, 234, 398-409.	4.5	17
54	Proteaseâ€activated receptorâ€1 drives pancreatic cancer progression and chemoresistance. International Journal of Cancer, 2014, 135, 2294-2304.	5.1	58

#	Article	IF	Citations
55	Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax, 2014, 69, 152-160.	5.6	44
56	Mendelian randomization in inflammatory conditions â€“ the exception rather than the rule?. Atherosclerosis, 2014, 235, e221-e222.	0.8	0
57	Proteaseâ€activated receptorâ€2 induces migration of pancreatic cancer cells in an extracellular ATPâ€dependent manner. Journal of Thrombosis and Haemostasis, 2013, 11, 1892-1902.	3.8	33
58	CCAAT/Enhancer-Binding Protein Î´. American Journal of Pathology, 2013, 182, 1459-1460.	3.8	1
59	<scp>CCAAT</scp>/enhancerâ€binding protein delta (C/<scp>EBP</scp>Î´) plays a minor role in renal host defense against uropathogenic <scp>E</scp>scherichia coli. Transplant Infectious Disease, 2013, 15, E119-21.	1.7	1
60	Irradiated Riboflavin Diminishes the Aggressiveness of Melanoma In Vitro and In Vivo. PLoS ONE, 2013, 8, e54269.	2.5	31
61	Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model. PLoS ONE, 2013, 8, e61923.	2.5	16
62	Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice: Figure 1â€“. European Respiratory Journal, 2012, 40, 1056-1057.	6.7	6
63	CCAAT/enhancer-binding protein Î´ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9113-9118.	7.1	31
64	Characterization of coagulation factor synthesis in nine human primary cell types. Scientific Reports, 2012, 2, 787.	3.3	28
65	CCAAT-Enhancer Binding Protein Delta (C/EBPÎ´) Protects Against Klebsiella pneumoniaeâ€“Induced Pulmonary Infection: Potential Role for Macrophage Migration. Journal of Infectious Diseases, 2012, 206, 1826-1835.	4.0	17
66	The protein C pathway in cancer metastasis. Thrombosis Research, 2012, 129, S80-S84.	1.7	16
67	PAR-2 activation induces migration but not proliferation of pancreatic cancer cells. Thrombosis Research, 2012, 129, S191.	1.7	0
68	Thrombin induces pancreatic cancer cell survival during growth factor deprivation. Thrombosis Research, 2012, 129, S191.	1.7	0
69	The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia â€“ A Prospective Cohort Study. Journal of Rheumatology, 2012, 39, 1914-1917.	2.0	13
70	Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?. Journal of Cellular and Molecular Medicine, 2012, 16, 2035-2048.	3.6	52
71	Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resistance Updates, 2012, 15, 211-222.	14.4	24
72	Dichotomy in Hedgehog Signaling between Human Healthy Vessel and Atherosclerotic Plaques. Molecular Medicine, 2012, 18, 1122-1127.	4.4	12

#	Article	IF	Citations
73	Insights Into the Mechanism of Zymogen Protein C Protection Against Cancer Progression. Blood, 2012, 120, 3350-3350.	1.4	1
74	Violacein Induces Death of Resistant Leukaemia Cells via Kinome Reprogramming, Endoplasmic Reticulum Stress and Golgi Apparatus Collapse. PLoS ONE, 2012, 7, e45362.	2.5	42
75	Abstract B48: Protease-activated receptor 2 in the microenvironment drives lymphangiogenesis and subsequent lymph metastasis in a murine pancreatic cancer model.. , 2012, , .		0
76	Abstract A78: PAR-2 activation with ATP facilitation induces migration but not proliferation of pancreatic cancer cells.. , 2012, , .		0
77	Blood coagulation factor Xa as an emerging drug target. Expert Opinion on Therapeutic Targets, 2011, 15, 341-349.	3.4	29
78	Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation. Cancer Letters, 2011, 306, 106-110.	7.2	16
79	Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis. Molecular Medicine, 2011, 17, 1119-1126.	4.4	13
80	Response to Comment on â€œTissue Factor-Dependent Chemokine Production Aggravates Experimental Colitisâ€• Molecular Medicine, 2011, 17, 1132-1132.	4.4	0
81	The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades. Current Pharmaceutical Design, 2011, 17, 9-16.	1.9	20
82	Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood, 2011, 118, 2889-2895.	1.4	68
83	mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome. Journal of Clinical Oncology, 2011, 29, e150-e153.	1.6	78
84	The Role of Activated Protein C in Cancer. Blood, 2011, 118, SCI-18-SCI-18.	1.4	0
85	Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Critical Care Medicine, 2010, 38, 457-463.	0.9	61
86	Protease-Activated Receptor 2 Blocking Peptide Counteracts Endotoxin-Induced Inflammation and Coagulation and Ameliorates Renal Fibrin Deposition in a Rat Model of Acute Renal Failure. Shock, 2010, 33, 339.	2.1	3
87	The coagulation factor Xa/protease activated receptorâ€2 axis in the progression of liver fibrosis: a multifaceted paradigm. Journal of Cellular and Molecular Medicine, 2010, 14, 143-153.	3.6	25
88	PTX3 predicts severe disease in febrile patients at the emergency department. Journal of Infection, 2010, 60, 122-127.	3.3	32
89	Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Research and Therapy, 2010, 7, 9.	1.7	40
90	Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene, 2010, 29, 6314-6322.	5.9	129

#	Article	IF	Citations
91	The Hedgehog morphogen in myocardial ischemiaâ€“reperfusion injury. Experimental Biology and Medicine, 2010, 235, 447-454.	2.4	12
92	Assessing the efficacy of the Hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 79-88.	3.4	32
93	Canonical Hedgehog signaling drives proangiogenic responses in endothelial cells. Cell Cycle, 2010, 9, 1678-1683.	2.6	5
94	Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver. Thrombosis Research, 2010, 125, 235-238.	1.7	3
95	Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thrombosis Research, 2010, 125, e323-e328.	1.7	24
96	Experimental and clinical effects of anticoagulants on cancer progression. Thrombosis Research, 2010, 125, S77-S79.	1.7	3
97	The role of activated protein C in cancer progression. Thrombosis Research, 2010, 125, S138-S142.	1.7	12
98	Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury. American Journal of Pathology, 2010, 177, 2753-2764.	3.8	55
99	Human Plasma Very Low Density Lipoprotein Carries Indian Hedgehog. Journal of Proteome Research, 2010, 9, 6052-6059.	3.7	47
100	A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx. PLoS ONE, 2010, 5, e11200.	2.5	11
101	Pivotal role of Proteaseâ€activated receptorâ€2 in bleomycinâ€induced pulmonary fibrosis. FASEB Journal, 2010, 24, 31.8.	0.5	0
102	Zymogen Protein C as a Novel Modulator of Cancer Progression In Murine Models. Blood, 2010, 116, 718-718.	1.4	0
103	Novel human pathological mutations. Gene symbol: PROS1. Disease: Protein S deficiency. Human Genetics, 2010, 127, 121.	3.8	1
104	Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2009, 68, 1654-1654.	0.9	12
105	Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19497-19502.	7.1	139
106	Gene Expression Profiles in Murine Influenza Pneumonia. Journal of Innate Immunity, 2009, 1, 366-375.	3.8	7
107	Activated Protein C Protects Against Myocardial Ischemia/ Reperfusion Injury via Inhibition of Apoptosis and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1087-1092.	2.4	73
108	Hypoxia induces a hedgehog response mediated by HIFâ€1Î±. Journal of Cellular and Molecular Medicine, 2009, 13, 2053-2060.	3.6	83

#	Article	IF	Citations
109	FXa-induced intracellular signaling links coagulation to neoangiogenesis: Potential implications for fibrosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 798-805.	4.1	12
110	Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency. Human Genetics, 2009, 126, 449-456.	3.8	41
111	Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clinical and Experimental Metastasis, 2009, 26, 171-178.	3.3	28
112	A mechanism for thrombinâ€dependent lung metastasis in patients with osteosarcoma. British Journal of Haematology, 2009, 145, 548-550.	2.5	3
113	Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. Journal of Thrombosis and Haemostasis, 2009, 7, 290-298.	3.8	38
114	Longâ€term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. Journal of Thrombosis and Haemostasis, 2009, 7, 1595-1597.	3.8	15
115	Letter in response to 'Coagulation and fibrosis in chronic liver disease'. Gut, 2009, 58, 1565-1566.	12.1	2
116	Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity. Thrombosis Research, 2009, 123, 914-918.	1.7	3
117	Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation. Thrombosis Research, 2009, 124, 219-225.	1.7	19
118	Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?. Trends in Pharmacological Sciences, 2009, 30, 8-16.	8.7	23
119	C-Reactive Protein Elicits White Blood Cell Activation in Humans. American Journal of Medicine, 2009, 122, 582.e1-582.e9.	1.5	34
120	Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1â€“mediated vascular endothelial barrier enhancement. Blood, 2009, 114, 1968-1973.	1.4	76
121	Leukotriene Synthesis Is Required for Hedgehog-Dependent Neurite Projection in Neuralized Embryoid Bodies but Not for Motor Neuron Differentiation. Stem Cells, 2008, 26, 1138-1145.	3.2	29
122	TF:FVIIaâ€specific activation of CREB upregulates proapoptotic proteins via proteaseâ€activated receptorâ€2. Journal of Thrombosis and Haemostasis, 2008, 6, 1550-1557.	3.8	13
123	Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies. Ecological Management and Restoration, 2008, 21, 628-633.	0.4	5
124	Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. Journal of Cellular and Molecular Medicine, 2008, 12, 2622-2627.	3.6	49
125	(Pro-)vitamin D as treatment option for hedgehog-related malignancies. Medical Hypotheses, 2008, 70, 202-203.	1.5	14
126	Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends in Molecular Medicine, 2008, 14, 429-440.	6.7	158

#	Article	IF	Citations
127	Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation. American Journal of Pathology, 2008, 172, 309-320.	3.8	116
128	Endogenous Hedgehog Expression Contributes to Myocardial Ischemia-Reperfusionâ€“Induced Injury. Experimental Biology and Medicine, 2008, 233, 989-996.	2.4	36
129	High factor VIIa levels do not promote tumor metastasis. Thrombosis and Haemostasis, 2008, 99, 787-788.	3.4	6
130	Differential Gene Expression Changes in Children with Severe Dengue Virus Infections. PLoS Neglected Tropical Diseases, 2008, 2, e215.	3.0	45
131	A comparative Analysis by SAGE of Gene Expression Profiles of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma. Analytical Cellular Pathology, 2008, 30, 63-75.	1.4	17
132	Protease-Activated Receptors, Apoptosis and Tumor Growth. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 137-147.	0.3	12
133	Gene Expression Profiling Identifies C/EBPÎ´ as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 602-609.	5.6	16
134	Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood, 2007, 110, 3176-3182.	1.4	65
135	Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice. Blood Coagulation and Fibrinolysis, 2007, 18, 627-636.	1.0	9
136	OC-08 Effects of low-molecular-weight heparins on metastatic tumor development in animal models. Thrombosis Research, 2007, 120, S143-S144.	1.7	1
137	Factor V Leiden and the etiology of inflammatory bowel disease. Thrombosis and Haemostasis, 2007, 98, 670-673.	3.4	8
138	Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. Cellular Signalling, 2007, 19, 2596-2604.	3.6	92
139	Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Experimental Cell Research, 2007, 313, 2622-2633.	2.6	25
140	Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. Journal of Cellular and Molecular Medicine, 2007, 11, 561-568.	3.6	12
141	Signal transduction induced by activated protein C: no role in protection against sepsis?. Trends in Molecular Medicine, 2006, 12, 374-381.	6.7	11
142	Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thrombosis and Haemostasis, 2006, 96, 789-793.	3.4	23
143	Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia*. Critical Care Medicine, 2006, 34, 1725-1730.	0.9	93
144	Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice*. Critical Care Medicine, 2006, 34, 2201-2206.	0.9	41

#	Article	IF	Citations
145	Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thrombosis Journal, 2006, 4, 13.	2.1	23
146	Alternatively spliced tissue factor in mice: induction by Streptococcus pneumoniae. Journal of Thrombosis and Haemostasis, 2006, 4, 918-920.	3.8	10
147	Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. British Journal of Pharmacology, 2006, 149, 740-746.	5.4	44
148	Hedgehog Turns Lipoproteins Into Janus-Faced Particles. Trends in Cardiovascular Medicine, 2006, 16, 217-220.	4.9	6
149	Hedgehog Morphogen in Cardiovascular Disease. Circulation, 2006, 114, 1985-1991.	1.6	44
150	Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin. European Respiratory Journal, 2006, 28, 622-626.	6.7	53
151	Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2288-2288.	2.4	213
152	A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling?. Development (Cambridge), 2006, 133, 3951-3951.	2.5	8
153	Repression of Smoothened by Patched-Dependent (Pro-)Vitamin D3 Secretion. PLoS Biology, 2006, 4, e232.	5.6	260
154	Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thrombosis and Haemostasis, 2006, 96, 789-93.	3.4	13
155	Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*. Critical Care Medicine, 2005, 33, 1365-1370.	0.9	72
156	High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood, 2005, 105, 2000-2006.	1.4	26
157	Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. Journal of Thrombosis and Haemostasis, 2005, 3, 2738-2744.	3.8	10
158	Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohnâ€™s disease patients. Journal of Molecular Medicine, 2005, 83, 601-609.	3.9	53
159	Functional Evolution of Tissue Factor, the Archetype of the Cytokine Receptor Family. Current Genomics, 2005, 6, 367-373.	1.6	2
160	Editorial [Hot Topic: Understanding and Treatment of Diseases in the Haemostatic System (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	0
161	RNA-Based Gene Therapy for Haemophilia B. Current Genomics, 2005, 6, 401-404.	1.6	0
162	Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology. Current Genomics, 2005, 6, 383-400.	1.6	0

#	Article	IF	Citations
163	Blood coagulation factors as inflammatory mediators. Blood Cells, Molecules, and Diseases, 2005, 34, 30-37.	1.4	56
164	Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 878-884.	5.6	142
165	Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways. Molecular Medicine, 2004, 10, 6-11.	4.4	97
166	Inhibition of the Tissue Factor/Factor VIIa Pathway Does Not Influence the Inflammatory or Antibacterial Response to Abdominal Sepsis Induced byEscherichia coliin Mice. Journal of Infectious Diseases, 2004, 189, 2308-2317.	4.0	50
167	FVIIa:TF Induces Cell Survival via G12/G13-Dependent Jak/STAT Activation and BclXLProduction. Circulation Research, 2004, 94, 1032-1040.	4.5	50
168	Concerted action of coagulation factors on cell survival. Journal of Thrombosis and Haemostasis, 2004, 2, 673-674.	3.8	4
169	Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. Journal of Thrombosis and Haemostasis, 2004, 2, 2185-2193.	3.8	14
170	Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene, 2004, 23, 410-417.	5.9	95
171	Hedgehog: an unusual signal transducer. BioEssays, 2004, 26, 387-394.	2.5	97
172	Blood cell-derived tissue factor influences host response during murine endotoxemia. Blood Cells, Molecules, and Diseases, 2004, 32, 325-333.	1.4	15
173	Tissue factor. Blood Coagulation and Fibrinolysis, 2004, 15, S3-S10.	1.0	14
174	Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. Journal of Clinical Immunology, 2003, 23, 132-140.	3.8	53
175	Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Research in Cardiology, 2003, 98, 347-352.	5.9	19
176	Regulation of the p21Ras-MAP kinase pathway by factor VIIa. Journal of Thrombosis and Haemostasis, 2003, 1, 1012-1018.	3.8	14
177	Tissue factor signal transduction in angiogenesis. Carcinogenesis, 2003, 24, 1009-1013.	2.8	58
178	Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Research, 2003, 31, 153e-153.	14.5	139
179	Effects of IC14, an Antiâ€CD14 Antibody, on Coagulation and Fibrinolysis during Lowâ€Grade Endotoxemia in Humans. Journal of Infectious Diseases, 2003, 187, 55-61.	4.0	39
180	Disseminated intravascular coagulation. The Hematology Journal, 2003, 4, 295-302.	1.4	60

#	Article	IF	Citations
181	In silico tissue factor analysis: a bit-to-bit comparison. Thrombosis and Haemostasis, 2003, 89, 592-593.	3.4	10
182	In silico tissue factor analysis: a bit-to-bit comparison. Thrombosis and Haemostasis, 2003, 89, 592-3.	3.4	0
183	Type I diabetes: a role for tissue factor in pancreatic islet transplantation?. Lancet, The, 2002, 360, 1999-2000.	13.7	5
184	The Pleiotropic Effects of Tissue Factor: a Possible Role for Factor VIIa-induced Intracellular Signalling?. Thrombosis and Haemostasis, 2001, 86, 1353-1359.	3.4	84
185	Microvascular coagulopathy and disseminated intravascular coagulation. Critical Care Medicine, 2001, 29, S95-S97.	0.9	60
186	The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 2000, 96, 554-559.	1.4	192
187	Genetic Risk Factors for Venous Thrombosis. Molecular Genetics and Metabolism, 2000, 71, 51-61.	1.1	16
188	Type-I Protein-C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein-C Gene Promoter. Trends in Cardiovascular Medicine, 1999, 9, 82-85.	4.9	4
189	Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity. Biochemical Journal, 1999, 340, 513.	3.7	1
190	Identification of Evolutionarily Invariant Sequences in the Protein C Gene Promoter. Journal of Molecular Evolution, 1998, 47, 663-669.	1.8	7
191	Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter. Journal of Biological Chemistry, 1998, 273, 10168-10173.	3.4	30
192	Promoter analysis of the auxin-regulated tobacco glutathione S-transferase genes Nt103-1 and Nt103-35. Plant Molecular Biology, 1995, 29, 413-429.	3.9	47
193	Genotypic Variation in the Promoter Region of the Protein C Gene Is Associated With Plasma Protein C Levels and Thrombotic Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 214-218.	2.4	105
194	Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites. Journal of Biological Chemistry, 1995, 270, 24216-24221.	3.4	43
195	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 0, , .	0.3	3
196	The anti-coagulants ASIS or APC do not protect against renal ischemia/ reperfusion injury. ScienceOpen Research, 0, , .	0.6	0